Veteran private equity and growth investor with a background in healthcare and technology deals, focused on value-oriented buyouts, growth equity and operational improvement. Brian Runkles is known for sourcing cross-border carve-outs, leading board-level strategy and driving EBITDA expansion through commercial scaling and cost discipline. Experience spans portfolio operational oversight, capital structuring and exits via strategic sales and IPOs, appealing to limited partners seeking active governance and sector specialization.
Veteran private equity and growth investor with a background in healthcare and technology deals, focused on value-oriented buyouts, growth equity and operational improvement. Brian Runkles is known for sourcing cross-border carve-outs, leading board-level strategy and driving EBITDA expansion through commercial scaling and cost discipline. Experience spans portfolio operational oversight, capital structuring and exits via strategic sales and IPOs, appealing to limited partners seeking active governance and sector specialization.
Focuses on value-oriented buyouts and growth equity in healthcare and technology, favoring cross-border carve-outs and complex corporate divestitures. Investment style emphasizes operational improvement and commercial scaling to drive EBITDA expansion, with active board governance and hands-on portfolio oversight. Capital allocation favors disciplined leverage and staged capital deployment, aligning incentives for exits via strategic sale or IPO. Strategy prioritizes sector specialization, margin expansion, and repeatable playbooks that de-risk mid-term value creation.
Focuses on value-oriented buyouts and growth equity in healthcare and technology, favoring cross-border carve-outs and complex corporate divestitures. Investment style emphasizes operational improvement and commercial scaling to drive EBITDA expansion, with active board governance and hands-on portfolio oversight. Capital allocation favors disciplined leverage and staged capital deployment, aligning incentives for exits via strategic sale or IPO. Strategy prioritizes sector specialization, margin expansion, and repeatable playbooks that de-risk mid-term value creation.
| Trades 557 | Longs Won 416/557 74% | Profit Factor 24.06 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $381,992.06 |
| Average Win $106,780.24 | Best Trade (Jul 10) $6.54M | Sharpe Ratio -12.51 |
| Average Loss -$13,092.34 | Worst Trade (Mar 31) -$363,923.12 | Z-Score 17.83 (100%) |
| Commissions $0 | Avg. Trade Length 10m 3w 4d | Expectancy $76,435.48 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 17,241 | 15,517 | 13,793 | 12,069 | 10,345 | 8,621 | 6,897 | 5,172 | 3,448 | 1,724 |